SCHEMBL554471

SCHEMBL554471

OC[C@@H]1CNCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17137 1.00
SCHEMBL619548 1.00
Hydrochloric Acid SCHEMBL352613 0.98
Hydrochloric Acid SCHEMBL16333974 0.98
Hydrochloric Acid SCHEMBL15573075 0.98
Oxalic Acid SCHEMBL351294 0.90 SLC6A2 (0.36)
Oxalic Acid SCHEMBL352319 0.90 SLC6A2 (0.36)
SCHEMBL352271 0.87 MEN1 (0.38)
SCHEMBL2794448 0.86
SCHEMBL16932248 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 428 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4027995-B1 HPK1 ANTAGONISTS AND USES THEREOF NIMBUS SATURN INC (US) 2026-05-27 EP disclosed
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 EP disclosed
US-20260062425-A1 AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2026-03-05 US disclosed
EP-4680601-A1 PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES Sanofi (FR) 2026-01-21 EP disclosed
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2025-12-23 US disclosed
US-12466815-B2 Carboxamide compounds and uses thereof INCYTE CORPORATION (US) 2025-11-11 US disclosed
US-20250339552-A1 ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE ZYMEWORKS BC INC (CA) 2025-11-06 US disclosed
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 US disclosed
US-12433952-B2 Antibody-drug conjugates targeting folate receptor alpha and methods of use ZYMEWORKS BC INC. (CA) 2025-10-07 US disclosed
US-20250295799-A1 ANTIBODY-DRUG CONJUGATES TARGETING GLYPICAN-3 AND METHODS OF USE ZYMEWORKS BC INC. (CA) 2025-09-25 US disclosed
US-20050222153-A1 C-6 modified indazolylpyrrolotriazines VITE GREGORY D 2005-10-06 US disclosed
EP-1569937-A2 C-6 MODIFIED INDAZOLYLPYRROLOTRIAZINES Bristol-Myers Squibb Company (US) 2005-09-07 EP disclosed
US-6916815-B2 C-6 modified indazolylpyrrolotriazines BRISTOL-MYERS SQUIBB COMPANY (US) 2005-07-12 US disclosed
WO-2005026152-A1 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS ASTRAZENECA AB (SE) 2005-03-24 WO disclosed
US-20040142931-A1 C-6 modified indazolylpyrrolotriazines BRISTOL-MYERS SQUIBB COMPANY 2004-07-22 US disclosed
WO-2004054514-A2 C-6 MODIFIED INDAZOLYLPYRROLOTRIAZINES BRISTOL-MYERS SQUIBB COMPANY (US) 2004-07-01 WO disclosed
US-5191079-A Chemical intermediates for bactericides KANEBO, LTD. (JP) 1993-03-02 US disclosed
US-5166203-A QUINOLINECARBOXYLIC ACID DERIVATIVES, ANTIBACTERIAL AGENT CONTAINING THE SAME KANEBO, LTD. (JP) 1992-11-24 US disclosed
CN-1059339-A New quinoline carboxylic acid derivative, the antiseptic-germicide that contains them and their method for making KANEBO LTD (JP) 1992-03-11 CN disclosed
EP-0472826-A2 Novel quinolinecarboxylic acid derivatives, use thereof, antibacterial agent containing the same, process for preparing said compounds and intermediate compound KANEBO LTD. (JP) 1992-03-04 EP disclosed